Legal & General Group
IKT icon

Legal & General Group’s Inhibikase Therapeutics IKT Stock Holding History

Legal & General Group’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.8K Buy
9,404
+3,900
+71% +$6.92K ﹤0.01% 3048
2025
Q4 		$11.3K Hold
5,504
– – ﹤0.01% 3219
2025
Q3 		$8.89K Hold
5,504
– – ﹤0.01% 3311
2025
Q2 		$10.7K Buy
+5,504
New +$10.8K ﹤0.01% 3268

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Legal & General Group's IKT Position: Q1 2026 in Review

Legal & General Group increased its Inhibikase Therapeutics (IKT) stake by 71% in Q1 2026, buying an estimated $6.92K and bringing the position to 9,404 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3048.

Legal & General Group first reported a position in IKT in Q2 2025 and has held it in 4 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Legal & General Group held 9,404 shares of Inhibikase Therapeutics worth $15.8K as of Q1 2026.
  • Legal & General Group bought 3,900 Inhibikase Therapeutics shares in Q1 2026, an estimated $6.92K.
  • Inhibikase Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3048 holding.
  • Legal & General Group first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.